TotipotentRX Corporation is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. We operate three distinct businesses to serve patients, physicians and partners: Therapeutics Division Contract Services Division Cell Manufacturing an…
TotipotentRX Corporation is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. We operate three distinct businesses to serve patients, physicians and partners: Therapeutics Division Contract Services Division Cell Manufacturing and Banking Division The company has developed 10 autologous 60-90 minute bedside treatments in the areas of cardiology, vascular, and orthopedic medicine. TotipotentRX announced the significant top line results of its Phase Ib (safety and efficacy) trial for no-option critical limb ischemia in January 2014.
Team (1)
Sectors TotipotentRX serves:
Life Sciences
Health Care
Join Axial's Private M&A Platform
TotipotentRX connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
